Myeloid progenitor cells from high-risk MDS patients additionally overexpress CD47, which is a surface anti-phagocytic molecule abnormally expressed on tumor cells that binds to its receptor Signal regulatory protein alpha (SIRPa) on macrophages and inhibits phagocytosis, counteracting CRT [146], [Figure 4]. This evidence concerns the gene SIRPA and neoplasm.